Zoster Vaccine Market Size & Share, By Product Type (Zostavax, Shingrix, SKYZoster), Vaccine Type (Live Attenuated Vaccine, Recombinant Vaccine), Sales Channel (Public, Private), Age Group (Above 50 to 65 Age, Above 65 Age, Above 18 to 50 Age), Regional Forecast, Industry Players, Growth Statistics Report 2024-2035

Market Outlook:

Zoster Vaccine Market size exceeded USD 52.29 Million in 2023 and is estimated to cross USD 289.4 Million by 2035, growing at over 21.42% CAGR during 2024 to 2035.

• Base Year Value (2023): USD 52.29 Million
• CAGR (2024-2035): 21.42%
• Forecast Year Value (2035): USD 289.4 Million
• Historical Data Period: 2019-2022
• Largest Region: North America
• Forecast Period: 2024-2035

Market Dynamics:

Growth Drivers & Opportunities

The global zoster vaccine market is expected to witness significant growth in the coming years, driven by several factors such as the growing geriatric population, increasing awareness about the importance of vaccination, and the rising prevalence of herpes zoster. According to the Centers for Disease Control and Prevention (CDC), nearly one out of every three people in the United States will develop shingles at some point in their lifetime, making it a major public health concern. This has led to a surge in demand for zoster vaccines, as they are considered to be an effective preventive measure against the infection.

Furthermore, advancements in healthcare infrastructure and the availability of government initiatives and programs promoting vaccination are also anticipated to contribute to the market growth. The expansion of immunization programs in developing countries, along with the introduction of new and improved vaccines, is expected to create lucrative opportunities for market players. Additionally, the growing adoption of combination vaccines, which offer protection against multiple diseases in a single shot, is likely to drive the market growth.

Industry Restraints & Challenges

Report Scope

Report Coverage	Details
Segments Covered	By Product Type, Vaccine Type, Sales Channel, Age Group
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	GlaxoSmithKline plc, Merck & Co., SK Biosciences, Geneone Life Science, Pfizer, CanSino Biologics, Vaccitech, Inovio Pharmaceuticals, Curevo,

Despite the promising growth prospects, the zoster vaccine market is expected to face certain restraints and challenges. One of the major challenges is the high cost of vaccines, which can limit their accessibility, especially in developing countries. Moreover, the lack of awareness about the benefits of vaccination, particularly among the elderly population, is likely to impede the market growth. The reluctance of some individuals to get vaccinated due to misconceptions and myths surrounding vaccines may also pose a challenge for market players. In addition, the stringent regulatory requirements and lengthy approval processes for new vaccines can hinder market expansion.

Regional Forecast:

North America

North America is expected to dominate the global zoster vaccine market, owing to the high prevalence of herpes zoster in the region. The presence of well-established healthcare infrastructure, coupled with a strong emphasis on disease prevention and immunization, is anticipated to drive market growth. In addition, the availability of advanced vaccines such as Shingrix and Zostavax, along with favorable reimbursement policies, is likely to contribute to the market expansion in North America.

Asia Pacific

The Asia Pacific region is poised to witness significant growth in the zoster vaccine market, driven by factors such as the increasing geriatric population, rising healthcare expenditure, and growing awareness about vaccination. The region is also characterized by the presence of a large pool of unvaccinated individuals, presenting a lucrative opportunity for market players to expand their reach. Moreover, government initiatives aimed at promoting immunization and the introduction of novel vaccines are expected to fuel market growth in Asia Pacific.

Europe

Europe is expected to exhibit steady growth in the zoster vaccine market, attributed to the high adoption of vaccination and the presence of well-established healthcare systems. The increasing geriatric population and the growing burden of herpes zoster in the region are anticipated to drive market growth. Furthermore, the availability of reimbursement for vaccines and the presence of key market players are likely to contribute to the market expansion in Europe.

In conclusion, the global zoster vaccine market is poised for significant growth, driven by factors such as the increasing prevalence of herpes zoster, growing awareness about vaccination, and the deployment of immunization programs. However, the market is not without its challenges, such as the high cost of vaccines and the lack of awareness among certain population groups. Nevertheless, with the expansion of healthcare infrastructure and the introduction of new and improved vaccines, the zoster vaccine market is expected to offer lucrative opportunities for market players across different regions.

Segmentation Analysis:

- Live Attenuated Vaccine

- Zostavax: This sub-segment is focused on the live attenuated vaccine, Zostavax, which is authorized for the prevention of herpes zoster in individuals aged 50 years and older. This vaccine contains a weakened form of the varicella-zoster virus, which helps the body build immunity to the virus and reduces the risk of developing shingles.

- Recombinant Subunit Vaccine

- Shingrix: Shingrix is a recombinant subunit vaccine that provides strong protection against herpes zoster and postherpetic neuralgia. It contains a single protein from the varicella-zoster virus, along with an adjuvant to enhance the body's immune response. This sub-segment has witnessed significant growth due to the high efficacy and safety profile of Shingrix.

Competitive Landscape:

The zoster vaccine market is characterized by the presence of several key players, including pharmaceutical companies, biotechnology firms, and vaccine manufacturers. These market players are actively involved in research and development activities to introduce new and improved vaccines, as well as expansion strategies to strengthen their market position. Some of the prominent companies operating in the zoster vaccine market include Merck & Co., Inc., GlaxoSmithKline plc, Sanofi Pasteur, Pfizer Inc., and Takeda Pharmaceutical Company Limited.

These companies are focused on advancing their vaccine technologies, conducting clinical trials, and obtaining regulatory approvals to launch innovative zoster vaccines. In addition, strategic collaborations, partnerships, and acquisitions are commonly observed in the market to expand product offerings and geographical presence. For instance, in 2018, GlaxoSmithKline plc entered into a strategic partnership with China National Biotech Group to help meet the growing demand for Shingrix in China.

Moreover, the competitive landscape is also influenced by the increasing emphasis on vaccination programs and initiatives by governments and healthcare organizations to reduce the burden of herpes zoster and its associated complications. This has led to enhanced market competition, as companies strive to address the unmet medical needs and improve access to zoster vaccines for a larger population.

Furthermore, market players are actively engaged in promotional and marketing activities to raise awareness about the importance of zoster vaccination and the benefits of immunization. This includes educational campaigns, disease awareness programs, and patient outreach efforts to encourage vaccination uptake among at-risk individuals, especially older adults.

In conclusion, the zoster vaccine market is witnessing significant growth and evolution, driven by the introduction of advanced vaccine formulations and the expanding focus on vaccination programs. The competitive landscape is characterized by the presence of key players who are committed to innovation, strategic collaborations, and public health initiatives to enhance the prevention and control of herpes zoster. With ongoing research and development efforts, the market is expected to offer lucrative opportunities for market players to address the global burden of shingles and improve public health outcomes.